BTIG raises Guardant Health stock price target on growth outlook
BTIG raised its price target for Guardant Health (GH) to $210 from $195, citing strong growth outlook. The firm expects Q3 revenue to exceed estimates by 4%, with Shield volume up 258% YoY. GH's stock has risen 144.53% in the past year, currently trading at $173.25. The company reported Q2 revenue of $335M, up 44% YoY, and raised its full-year guidance.
How this was made
The 30-second read
Why it matters
The BTIG upgrade adds to a series of bullish analyst actions, reinforcing a positive momentum narrative.
Market read
Analyst target raise is a fresh catalyst that can drive short‑term buying interest in GH.
What to watch
Potential regulatory or reimbursement risks for Shield and G360 tests could temper growth.
Background
Guardant Health reported strong Q2 results and raised guidance, prompting multiple analysts to lift price targets.
Ticker impact
BTIG raised its price target on Guardant Health to $210 and maintained a Buy rating, citing strong Q3 revenue outlook and volume growth.
upward pressure as investors price in the higher target and growth expectations
Target raise is a fresh, material analyst action that can move the stock in the short term.
Market effects
Positive outlook may lift other liquid biopsy and precision oncology stocks.
U.S. biotech sector could see modest gains.
Limited to investors focused on U.S. biotech equities.
Counterpoint
The target raise may already be priced in after the recent 144% rally, limiting upside.
Key entities
- companyGuardant Health Inc.
U.S. liquid biopsy company (ticker GH).
- analystBTIG
Equity research firm that raised the price target.
